Ignite Creation Date:
2024-05-06 @ 12:31 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03787602
Status:
RECRUITING
Last Update Posted:
2023-03-02
First Post:
2018-12-06
Brief Title:
Navtemadlin KRT-232 With or Without Anti-PD-1Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Sponsor:
Organization:
Kartos Therapeutics Inc